Vitiligo
Definition
Causes
- The body’s immune system may destroy the melanocytes
- Melanocytes may destroy themselves
- Defective nerve cells may make toxic substances that harm the melanocytes
Risk Factors
- Family members with vitiligo or hair turning gray early
- Age: 10 to 30
- Certain autoimmune diseases such as thyroid disease
Symptoms
- Areas exposed to the sun such as the face, hands, arms, and upper part of the chest
- Areas around body openings such as the eyes, nostrils, mouth, navel, and genitals
- Body folds such as the groin and armpits
- Sites of chronic minor injury such as knuckles and elbows
- Sites of injury such as scrapes, cuts, and burns
- The area around moles
Diagnosis
Treatment
- Repigmentation—replace skin color in patches
- Slowing loss of color
- Decreasing the difference between affected and unaffected skin
PUVA (Psoralen plus UVA) and Narrow Band UVB (nbUVB)
Excimer Laser
Skin Creams
- Corticosteroid skin cream—can sometimes slow the loss of color. It may also help return color to small areas. It may cause thinning of the skin.
- Tacrolimus or pimecrolimus skin creams—can sometimes slow the loss of color. They can help return color to small areas. They may also cause thinning of the skin.
- Skin grafting —done if the condition is not widespread and stable. It may be possible to graft areas of normal pigmentation to the patches.
| Skin Graft |
|
| Copyright © Nucleus Medical Media, Inc. |
Depigmentation
Cosmetics
Sunscreen
- Protect the depigmented area from the damaging effects of sun exposure
- Prevent increased pigmentation of other areas
Prevention
RESOURCES
American Academy of Dermatology http://www.aad.org
National Vitiligo Foundation, Inc. http://www.mynvfi.org
CANADIAN RESOURCES
Canadian Dermatology Association http://www.dermatology.ca
Dermatologists.ca http://www.dermatologists.ca
References
Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br J Dermatol . 2008 Nov;159(5):1051-76.
Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol. 2005;44:57-60.
Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: A review. J Am Acad Dermatol . 2009 Jan 19.
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med . 2009 Jan 8;360(2):160-9.
Vitiligo. American Academy of Dermatology website. Available at: http://www.aad.org/dermatology-a-to-z/diseases-and-treatments/u---w/vitiligo . Accessed June 4, 2013.
Vitiligo. National Institute of Arthritis and Musculoskeletal and Skin Diseases website. Available at: http://www.niams.nih.gov/Health%5FInfo/Vitiligo/default.asp . Updated August 2010. Accessed June 4, 2013.
Vitiligo basics. National Vitiligo Foundation website. Available at: http://www.mynvfi.org/about%5Fvitiligo . Accessed June 4, 2013.
Revision Information
- Reviewer: Purvee S. Shah, MD; Michael Woods, MD
- Review Date: 06/2013 -
- Update Date: 06/04/2013 -